Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Phosphate Accelerates Cellular Cholesterol Efflux in THP-1 Cells

被引:4
|
作者
Komatsu, Tomohiro [1 ,2 ]
Abe, Satomi [1 ]
Nakashima, Shihoko [3 ]
Sasaki, Kei [2 ]
Higaki, Yasuki [1 ,3 ]
Saku, Keijiro [4 ]
Miura, Shin-ichiro [4 ]
Uehara, Yoshinari [1 ,2 ,3 ,4 ]
机构
[1] Fukuoka Univ, Res Inst Phys Act, 8-19-1 Nanakuma,Johnan Ku, Fukuoka 8140180, Japan
[2] Fukuoka Univ Hosp, Ctr Prevent Antiaging & Regenerat Med, 7-45-1 Nanakuma,Johnan Ku, Fukuoka 8140180, Japan
[3] Fukuoka Univ, Fac Sports & Hlth Sci, 8-19-1 Nanakuma,Johnan Ku, Fukuoka 8140180, Japan
[4] Fukuoka Univ Hosp, Dept Cardiol, 7-45-1 Nanakuma,Johnan Ku, Fukuoka 8140180, Japan
关键词
HDL; cholesterol efflux; DPP-4; inhibitor; GLP-1; ABCA1; apoA1; CASSETTE TRANSPORTER A1; TYPE-2; DIABETES-MELLITUS; FUNCTIONAL EXPRESSION; ATHEROSCLEROTIC LESION; SIGNAL-TRANSDUCTION; INSULIN-RESISTANCE; RECEPTOR AGONIST; HDL-CHOLESTEROL; GLP-1; RECEPTOR; FATTY-ACIDS;
D O I
10.3390/biom13020228
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cholesterol efflux is a major atheroprotective function of high-density lipoproteins (HDLs) which removes cholesterol from the foam cells of lipid-rich plaques in Type 2 diabetes. The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin phosphate increases plasma glucagon-like peptide-1 (GLP-1) concentrations and is used to treat Type 2 diabetes. GLP-1 plays an important role in regulating insulin secretion and expression via the GLP-1 receptor (GLP-1R), which is expressed in pancreatic islets as well as freshly isolated human monocytes and THP-1 cells. Here, we identified a direct role of GLP-1 and DPP-4 inhibition in HDL function. Cholesterol efflux was measured in cultivated phorbol 12-myristate 13-acetate-treated THP-1 cells radiolabeled with H-3-cholesterol and stimulated with liver X receptor/retinoid X receptor agonists. Contrary to vildagliptin, sitagliptin phosphate together with GLP-1 significantly (p < 0.01) elevated apolipoprotein (apo)A1-mediated cholesterol efflux in a dose-dependent manner. The sitagliptin-induced increase in cholesterol efflux did not occur in the absence of GLP-1. In contrast, adenosine triphosphate-binding cassette transporter A1 (ABCA1) mRNA and protein expressions in the whole cell fraction were not changed by sitagliptin in the presence of GLP-1, although sitagliptin treatment significantly increased ABCA1 protein expression in the membrane fraction. Furthermore, the sitagliptin-induced, elevated efflux in the presence of GLP-1 was significantly decreased by a GLP-1R antagonist, an effect that was not observed with a protein kinase A inhibitor. To our knowledge, the present study reports for the first time that sitagliptin elevates cholesterol efflux in cultivated macrophages and may exert anti-atherosclerotic actions that are independent of improvements in glucose metabolism. Our results suggest that sitagliptin enhances HDL function by inducing a de novo HDL synthesis via cholesterol efflux.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] The effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on gentamicin nephrotoxicity in mice
    Al Suleimani, Yousuf M.
    Abdelrahman, Aly M.
    Karaca, Turan
    Manoj, Priyadarsini
    Ashique, Mohammed
    Nemmar, Abderrahim
    Ali, Badreldin H.
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 97 : 1102 - 1108
  • [2] Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
    Bergman, Arthur J.
    Cote, Josee
    Yi, Bingming
    Marbury, Thomas
    Swan, Suzanne K.
    Smith, William
    Gottesdiener, Keith
    Wagner, John
    Herman, Gary A.
    DIABETES CARE, 2007, 30 (07) : 1862 - 1864
  • [3] The Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Gentamicin Nephrotoxicity in Mice
    Ali, Badreldin H.
    Suleimani, Yousuf M.
    Abdelrahman, Aly M.
    Karaca, Turan
    Nemmar, Abderrahim
    FASEB JOURNAL, 2018, 32 (01):
  • [4] Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers
    Bergman, Arthur
    Ebel, David
    Liu, Fang
    Stone, Julie
    Wang, Amy
    Zeng, Wei
    Chen, Li
    Dilzer, Stacy
    Lasseter, Kenneth
    Herman, Gary
    Wagner, John
    Krishna, Rajesh
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2007, 28 (06) : 315 - 322
  • [5] Stereoselective Synthesis of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, (R)-Sitagliptin
    Anjibabu, Ramisetti
    Boggu, Jagan Mohan Reddy
    Shekhar, Putta
    Reddy, Basi V. Subba
    CHEMISTRYSELECT, 2016, 1 (17): : 5445 - 5447
  • [6] Oral ulceration due to a dipeptidyl peptidase-4 inhibitor (sitagliptin): Report of a case
    Jinbu, Yoshinori
    Sase, Miwako
    Kashimura, Kei
    Itoh, Hiroto
    Kusama, Mikio
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY MEDICINE AND PATHOLOGY, 2013, 25 (02) : 164 - 166
  • [7] Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
    Mega, Cristina
    Teixeira-Lemos, Edite
    Fernandes, Rosa
    Reis, Flavio
    JOURNAL OF DIABETES RESEARCH, 2017, 2017
  • [8] Sensitive Spectrofluorimetric Methods for Determination of Sitagliptin Phosphate, Dipeptidyl Peptidase-4 Inhibitor, in Pharmaceutical Tablets and Spiked Human Urine
    Ali, Marwa F. Bakr
    Atia, Noha N.
    CURRENT PHARMACEUTICAL ANALYSIS, 2018, 14 (05) : 483 - 490
  • [9] Effects of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, on Colorectal Carcinogenesis in a Model of Type 2 Diabetes
    Inoue, Takuya
    Yorifuji, Naoki
    Fujiwara, Kaori
    Sakanaka, Taisuke
    Iguchi, Munetaka
    Narabayashi, Ken
    Okada, Toshihiko
    Nouda, Sadaharu
    Kakimoto, Kazuki
    Ishida, Kumi
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Umegaki, Eiji
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2014, 146 (05) : S654 - S655
  • [10] Dipeptidyl peptidase-4 inhibitor sitagliptin induces vasorelaxation via the activation of Kv channels and PKA
    Li, Hongliang
    Seo, Mi Seon
    An, Jin Ryeol
    Jung, Hee Seok
    Ha, Kwon-Soo
    Han, Eun-Taek
    Hong, Seok-Ho
    Bae, Young Min
    Na, Sung Hun
    Park, Won Sun
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2019, 384